Compare Cassava Sciences Inc (FLNA) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs KLA Corp. — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while KLA Corp. trades at $219.36 (market cap $293.26B). The key difference: KLA Corp. is far larger — about 5518.6× Cassava Sciences Inc's market cap, and KLA Corp. pays a 0.41% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | KLAC | |
|---|---|---|
Market Cap | $53.14M | $293.26B |
Sector | Health | Technology |
52-Week High | $4.64 | $301.71 |
52-Week Low | $1.09 | $84.39 |
Enterprise Value | -$33.43M | $294.45B |
Dividend Yield | — | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
KLA Corporation (KLAC) trades at $219.92, down 4.54% on the day, with technical indicators showing a neutral to bearish short-term bias. The stock exhibits strong fundamentals, including a 35.66% net income margin and consistent earnings beats, most recently in Q1 2026. Revenue grew to $12.16 billion in 2025, and a 1:10 stock split is scheduled for June 12, 2026. Analyst sentiment remains largely positive, with a consensus price target of $242.33 implying potential upside.
The outlook for KLAC is supported by its dominant position in semiconductor process control and AI-driven demand, though high valuation multiples (P/E of 63.58) pose a risk. Investors face exposure to semiconductor cycle volatility and competitive pressures, but the company's profitability and analyst bullishness suggest long-term growth potential if execution remains strong.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
